Tasigna FDA Approval History
FDA Approved: Yes (First approved October 29, 2007)
Brand name: Tasigna
Generic name: nilotinib
Dosage form: Capsules
Treatment for: Chronic Myelogenous Leukemia
Tasigna (nilotinib) is a kinase inhibitor indicated for the treatment of chronic phase and accelerated phase Philadelphia chromosome positive chronic myelogenous leukemia (CML).
Development timeline for Tasigna
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.